These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

5-Benzylidene-4-Oxazolidinones are Synergistic with Antibiotics for the Treatment of Staphylococcus Aureus Biofilms

submitted on 02.09.2019, 18:27 and posted on 05.09.2019, 04:33 by Bram Frohock, Jessica M. Gilbertie, Jennifer C. Daiker, Lauren V. Schnabel, Joshua Pierce
The failure of frontline antibiotics in the clinic is one of the most serious threats to human health and requires a multitude of novel therapeutics and innovative treatment approaches to curtail the growing crisis. In addition to traditional resistance mechanisms resulting in the lack of efficacy of many antibiotics, most chronic and recurring infections are further made tolerant to antibiotic action by the presence of biofilms. Herein, we report an expanded set of 5-benzylidene-4-oxazolidinones that are able to inhibit the formation of Staphylococcus aureus biofilms, disperse preformed biofilms and in combination with common antibiotics are able to significantly reduce the bacterial load in a robust collagen-matrix model of biofilm infection.


NIGMS, 1R01GM110154


Email Address of Submitting Author


NC State University



ORCID For Submitting Author


Declaration of Conflict of Interest

The authors declare the following competing financial interest(s): J.G.P. is a founder of Synoxa Sciences, Inc., a biotechnology company developing 4-oxazolidinones as antimicro-bial agents and anti-biofilm agents.